IL2 and neoplasm: The preferential interest in Vδ2 T cells can be explained by (i) well-characterized antigens, (ii) the ease to expand these T cells in vitro under good manufacturing practice conditions for adoptive transfer, (iii) the application of licensed drugs such as aminobisphosphonates and IL-2 to activate these cells in vivo, (iv) availability of bispecific antibodies as enhancer for Vγ9Vδ2 γδ T cell-mediated lysis of tumor cells and (v) high plasticity of Vδ2 T cells by combining the features of both innate and adaptive immunity [(30, 63–68) for review].